Cytokinetics to Participate in June Investor Conferences
2024年5月30日 - 5:00AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the
company is scheduled to participate in the following investor
conferences in June:
- Jefferies Global Healthcare
Conference: Robert I. Blum, President and Chief Executive
Officer, and Andrew Callos, Executive Vice President and Chief
Commercial Officer, will participate in a fireside chat on
Wednesday, June 5, 2024 at 2:00 PM Eastern Time at the New York
Marriott Marquis Hotel in New York, NY.
-
45th Annual Goldman Sachs
Healthcare Conference: Robert I. Blum, President and Chief
Executive Officer, and Andrew Callos, Executive Vice President and
Chief Commercial Officer, will participate in a fireside chat on
Monday, June 10, 2024 at 11:20 AM Eastern Time at the Loews Miami
Beach Hotel in Miami Beach, FL.
Interested parties may access the live webcasts
of the fireside chats by visiting the Investors & Media section
of the Cytokinetics website at http://www.cytokinetics.com. The
webcast replays will be archived on the Cytokinetics website for 90
days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory submissions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive results from SEQUOIA-HCM, the
pivotal Phase 3 clinical trial in obstructive hypertrophic
cardiomyopathy. Aficamten is also currently being evaluated in
MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy
compared to metoprolol as monotherapy in patients with obstructive
HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients
with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten
in a pediatric population with obstructive HCM, and FOREST-HCM, an
open-label extension clinical study of aficamten in patients with
HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac
muscle activator, in patients with heart failure. Additionally,
Cytokinetics is developing CK-586, a cardiac myosin inhibitor with
a mechanism of action distinct from aficamten for the potential
treatment of HFpEF, and CK-136, a cardiac troponin activator for
the potential treatment HFrEF and other types of heart failure,
such as right ventricular failure resulting from impaired cardiac
contractility.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped
logo are registered trademarks of Cytokinetics in the U.S. and
certain other countries.
Contact:Cytokinetics Diane WeiserSenior Vice President,
Corporate Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
過去 株価チャート
から 8 2024 まで 9 2024
Cytokinetics (NASDAQ:CYTK)
過去 株価チャート
から 9 2023 まで 9 2024